WO2020183437A1 - Systèmes et procédés pour détection spectrale d'agent pathogènes résistants aux médicaments. - Google Patents
Systèmes et procédés pour détection spectrale d'agent pathogènes résistants aux médicaments. Download PDFInfo
- Publication number
- WO2020183437A1 WO2020183437A1 PCT/IB2020/052339 IB2020052339W WO2020183437A1 WO 2020183437 A1 WO2020183437 A1 WO 2020183437A1 IB 2020052339 W IB2020052339 W IB 2020052339W WO 2020183437 A1 WO2020183437 A1 WO 2020183437A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sample
- treatment
- spectroscopy
- pathogen
- spectra
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 146
- 244000052769 pathogen Species 0.000 title claims abstract description 127
- 230000003595 spectral effect Effects 0.000 title claims description 122
- 239000003814 drug Substances 0.000 title description 73
- 229940079593 drug Drugs 0.000 title description 72
- 238000001514 detection method Methods 0.000 title description 7
- 238000001228 spectrum Methods 0.000 claims abstract description 135
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 106
- 238000011282 treatment Methods 0.000 claims abstract description 85
- 239000000523 sample Substances 0.000 claims description 280
- 238000012360 testing method Methods 0.000 claims description 114
- 238000004611 spectroscopical analysis Methods 0.000 claims description 64
- 238000012545 processing Methods 0.000 claims description 36
- 238000001069 Raman spectroscopy Methods 0.000 claims description 33
- 241000894006 Bacteria Species 0.000 claims description 32
- 238000012258 culturing Methods 0.000 claims description 31
- 238000002835 absorbance Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 239000013068 control sample Substances 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 238000005102 attenuated total reflection Methods 0.000 claims description 15
- 230000003115 biocidal effect Effects 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000004483 ATR-FTIR spectroscopy Methods 0.000 claims description 12
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 238000001237 Raman spectrum Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000001055 reflectance spectroscopy Methods 0.000 claims description 8
- 238000004497 NIR spectroscopy Methods 0.000 claims description 7
- 230000000843 anti-fungal effect Effects 0.000 claims description 7
- 238000010183 spectrum analysis Methods 0.000 claims description 7
- 238000002235 transmission spectroscopy Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 230000009120 phenotypic response Effects 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 238000001413 far-infrared spectroscopy Methods 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000000513 principal component analysis Methods 0.000 description 124
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 74
- 239000000126 substance Substances 0.000 description 74
- 210000004027 cell Anatomy 0.000 description 57
- 229960004755 ceftriaxone Drugs 0.000 description 46
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 46
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 46
- 229960001019 oxacillin Drugs 0.000 description 45
- 238000002329 infrared spectrum Methods 0.000 description 40
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 37
- 229930182566 Gentamicin Natural products 0.000 description 37
- 229960003405 ciprofloxacin Drugs 0.000 description 37
- 229960002518 gentamicin Drugs 0.000 description 37
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 35
- 108010059993 Vancomycin Proteins 0.000 description 34
- 229960003165 vancomycin Drugs 0.000 description 34
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 34
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 26
- 108010013639 Peptidoglycan Proteins 0.000 description 26
- 206010041925 Staphylococcal infections Diseases 0.000 description 25
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 25
- 230000000694 effects Effects 0.000 description 22
- 238000011534 incubation Methods 0.000 description 22
- 238000004891 communication Methods 0.000 description 21
- 238000011068 loading method Methods 0.000 description 21
- 230000012010 growth Effects 0.000 description 20
- 230000004044 response Effects 0.000 description 19
- 229960003022 amoxicillin Drugs 0.000 description 18
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 18
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 16
- 230000015654 memory Effects 0.000 description 15
- 229960003085 meticillin Drugs 0.000 description 15
- 239000008188 pellet Substances 0.000 description 15
- 238000005119 centrifugation Methods 0.000 description 14
- 229960002227 clindamycin Drugs 0.000 description 14
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 13
- 239000003085 diluting agent Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000013480 data collection Methods 0.000 description 11
- 241000588626 Acinetobacter baumannii Species 0.000 description 10
- 241000194031 Enterococcus faecium Species 0.000 description 9
- 230000006355 external stress Effects 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 238000010200 validation analysis Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 241000588747 Klebsiella pneumoniae Species 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000004566 IR spectroscopy Methods 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000013500 data storage Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000007781 pre-processing Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 238000003794 Gram staining Methods 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000017066 negative regulation of growth Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- -1 1480 cm 1 Chemical class 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 2
- 229910001634 calcium fluoride Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940124307 fluoroquinolone Drugs 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004066 metabolic change Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000010239 partial least squares discriminant analysis Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 241000588731 Hafnia Species 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229910008760 WITec Inorganic materials 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 238000001210 attenuated total reflectance infrared spectroscopy Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920000547 conjugated polymer Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013135 deep learning Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000011982 device technology Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- CJNBYAVZURUTKZ-UHFFFAOYSA-N hafnium(IV) oxide Inorganic materials O=[Hf]=O CJNBYAVZURUTKZ-UHFFFAOYSA-N 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 238000010897 surface acoustic wave method Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- GZXOHHPYODFEGO-UHFFFAOYSA-N triglycine sulfate Chemical class NCC(O)=O.NCC(O)=O.NCC(O)=O.OS(O)(=O)=O GZXOHHPYODFEGO-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/55—Specular reflectivity
- G01N21/552—Attenuated total reflection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/42—Low-temperature sample treatment, e.g. cryofixation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/44—Sample treatment involving radiation, e.g. heat
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/01—Arrangements or apparatus for facilitating the optical investigation
- G01N2021/0106—General arrangement of respective parts
- G01N2021/0118—Apparatus with remote processing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N2021/3595—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using FTIR
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N2021/751—Comparing reactive/non reactive substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Procédés de détermination de la susceptibilité ou de la résistance au traitement d'un agent pathogène comprenant la collecte de spectres à partir d'un agent pathogène cultivé avec un traitement et à partir du même agent pathogène cultivé sans le traitement. Les spectres sont comparés pour déterminer la susceptibilité ou la résistance de l'agent pathogène au traitement. L'invention concerne également des systèmes pour déterminer la susceptibilité ou la résistance au traitement d'un agent pathogène et peuvent comprendre un réseau informatique à distance, pouvant être basé sur un nuage.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962818039P | 2019-03-13 | 2019-03-13 | |
US62/818,039 | 2019-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020183437A1 true WO2020183437A1 (fr) | 2020-09-17 |
Family
ID=72426483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2020/052339 WO2020183437A1 (fr) | 2019-03-13 | 2020-03-13 | Systèmes et procédés pour détection spectrale d'agent pathogènes résistants aux médicaments. |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020183437A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023288096A1 (fr) * | 2021-07-16 | 2023-01-19 | The Regents Of The University Of California | Détermination rapide de maladie dans des cellules de substitution à l'aide d'une lumière infrarouge |
WO2023118904A1 (fr) * | 2021-12-23 | 2023-06-29 | The University Of Liverpool | Hydrogels et leurs utilisations |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990009454A1 (fr) * | 1989-02-09 | 1990-08-23 | Bruker Analytische Messtechnik Gmbh | Procede et dispositif pour tester rapidement l'efficacite d'agents chimiques sur des micro-organismes |
US20050123917A1 (en) * | 2001-11-12 | 2005-06-09 | Synthon Kg | Method for characterising and/or identifying active mechanisms of antimicrobial test substances |
US20160177366A1 (en) * | 2013-08-07 | 2016-06-23 | Seraph Biosciences, Llc | Hand-held micro-raman based detection instrument and method of detection |
US20180355399A1 (en) * | 2015-11-27 | 2018-12-13 | bioMérieux | Method for determining the reaction of a microorganism to its exposure to a chemical compound |
-
2020
- 2020-03-13 WO PCT/IB2020/052339 patent/WO2020183437A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990009454A1 (fr) * | 1989-02-09 | 1990-08-23 | Bruker Analytische Messtechnik Gmbh | Procede et dispositif pour tester rapidement l'efficacite d'agents chimiques sur des micro-organismes |
US20050123917A1 (en) * | 2001-11-12 | 2005-06-09 | Synthon Kg | Method for characterising and/or identifying active mechanisms of antimicrobial test substances |
US20160177366A1 (en) * | 2013-08-07 | 2016-06-23 | Seraph Biosciences, Llc | Hand-held micro-raman based detection instrument and method of detection |
US20180355399A1 (en) * | 2015-11-27 | 2018-12-13 | bioMérieux | Method for determining the reaction of a microorganism to its exposure to a chemical compound |
Non-Patent Citations (5)
Title |
---|
AJESH K. ET AL.: "Cryptococcus laurentii Biofilms: Structure, Development and Antifungal Drug Resistance", MYCOPATHOLOGIA, vol. 174, 2012, pages 409 - 419 * |
ATHAMNEH, A.I.M ET AL.: "Phenotypic Profiling of Antibiotic Response Signatures in Escherichia coli Using Raman Spectroscopy", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 58, no. 3, March 2014 (2014-03-01), pages 1302 - 1314, XP055290095, DOI: 10.1128/AAC.02098-13 * |
PREMASIRI W. R. ET AL.: "Rapid urinary tract infection diagnostics by surface-enhanced Raman spectroscopy (SERS): identification and antibiotic susceptibilities", ANAL BIOANAL CHEM, vol. 409, 2017, pages 3043 - 3054, XP036198155, DOI: 10.1007/s00216-017-0244-7 * |
QUILES F. ET AL.: "AFM combined to ATR-FTIR reveals Candida cell wall changes under caspofungin treatment", NANOSCALE, vol. 9, no. 36, 2017, pages 13731 - 13738, XP055739382 * |
SHARAHA U. ET AL.: "Using Infrared Spectroscopy and Multivariate Analysis to Detect Antibiotics' Resistant Escherichia coli Bacteria", ANAL. CHEM., vol. 89, no. 17, 5 September 2017 (2017-09-05), pages 8782 - 8790, XP055739386 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023288096A1 (fr) * | 2021-07-16 | 2023-01-19 | The Regents Of The University Of California | Détermination rapide de maladie dans des cellules de substitution à l'aide d'une lumière infrarouge |
WO2023118904A1 (fr) * | 2021-12-23 | 2023-06-29 | The University Of Liverpool | Hydrogels et leurs utilisations |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lasch et al. | FT-IR hyperspectral imaging and artificial neural network analysis for identification of pathogenic bacteria | |
Ciloglu et al. | Drug-resistant Staphylococcus aureus bacteria detection by combining surface-enhanced Raman spectroscopy (SERS) and deep learning techniques | |
US20190187048A1 (en) | Spectroscopic systems and methods for the identification and quantification of pathogens | |
Wu et al. | Differentiation and classification of bacteria using vancomycin functionalized silver nanorods array based surface-enhanced Raman spectroscopy and chemometric analysis | |
Kloß et al. | Toward culture-free Raman spectroscopic identification of pathogens in ascitic fluid | |
Kang et al. | Single-cell classification of foodborne pathogens using hyperspectral microscope imaging coupled with deep learning frameworks | |
Ayala et al. | Drug-resistant Staphylococcus aureus strains reveal distinct biochemical features with Raman microspectroscopy | |
Pomerantsev et al. | On the type II error in SIMCA method | |
Boggs et al. | Characterization of a Staphylococcus aureus USA300 protein signature using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry | |
Sousa et al. | Diverse high-risk B2 and D Escherichia coli clones depicted by Fourier Transform Infrared Spectroscopy | |
de Sousa Marques et al. | Feature selection strategies for identification of Staphylococcus aureus recovered in blood cultures using FT-IR spectroscopy successive projections algorithm for variable selection: A case study | |
WO2020183437A1 (fr) | Systèmes et procédés pour détection spectrale d'agent pathogènes résistants aux médicaments. | |
Barbosa et al. | A novel use of infra-red spectroscopy (NIRS and ATR-FTIR) coupled with variable selection algorithms for the identification of insect species (Diptera: Sarcophagidae) of medico-legal relevance | |
Xu et al. | High-speed diagnosis of bacterial pathogens at the single cell level by Raman microspectroscopy with machine learning filters and Denoising autoencoders | |
Wang et al. | Importance evaluation of spectral lines in Laser-induced breakdown spectroscopy for classification of pathogenic bacteria | |
Zhao et al. | Genetic variations associated with drug resistance markers in asymptomatic Plasmodium falciparum infections in Myanmar | |
Guo et al. | Model transfer for Raman‐spectroscopy‐based bacterial classification | |
Sharaha et al. | Detection of extended-spectrum β-lactamase-producing Escherichia coli using infrared microscopy and machine-learning algorithms | |
Rizzato et al. | Pushing the limits of MALDI-TOF mass spectrometry: beyond fungal species identification | |
Rees et al. | Detection of high-risk carbapenem-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates using volatile molecular profiles | |
Sharaha et al. | Determination of Klebsiella pneumoniae susceptibility to antibiotics using infrared microscopy | |
Lin et al. | Determination of causes of death via spectrochemical analysis of forensic autopsies‐based pulmonary edema fluid samples with deep learning algorithm | |
Ma et al. | Conditional generative adversarial network for spectral recovery to accelerate single-cell Raman spectroscopic analysis | |
Lu et al. | Identification of pathogens and detection of antibiotic susceptibility at single-cell resolution by Raman spectroscopy combined with machine learning | |
Schumacher et al. | Improving chemometric results by optimizing the dimension reduction for Raman spectral data sets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20770342 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20770342 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20770342 Country of ref document: EP Kind code of ref document: A1 |